The content at ACR Orlando was vast. I looked at several posters/listened to many talks and heard from colleagues. Here is my list TOP 6 practice changing themes.
All News
Article
Article
The last day of ACR 2026 was a half-day but a busy day, with several exciting reports, especially coming from the late-breaking abstracts.
anita
Tweet
@RheumNow Abstract #2483 Pediatric Sjögren’s lacks validated clinical trial endpoints, limiting treatment research. This study developed a prioritized, 8-domain patient-centered endpoint for N-of-1 trials, bridging objective disease activity and lived symptom burden. #ACR26
(1/2)#ACRBest Dazodalibep (DAZ) for systemically active SjD Ph3 top line results! LB22
648 pts
IV DAZ 1500mg Q4W or 3000mg Q12W vs placebo
Signf improved ESSDAI in both DAZ arms @ 48W. ESDAI differences vs placebo -1.8 for 1500mg Q4W, -1.4 for 3000mg Q12W
@RheumNow #ACR26
Brian Jaros, MD
Tweet
Dazodalibep (CD40/CD40L inhibitor) for Sjogren's
Improved ESSDAI at both doses compared to PBO
Q4 week dosing w/ improvements in dryness
Sig. improvement but PBO also did fairly well... how much is an ESSDAI delta of -1.4 to -1.8 clinically meaningful...
@RheumNow #ACR26 LB22 https://t.co/AEBtjpJq1F
Janet Pope
Tweet
#Sjogren’s is no longer a
#dry #Rx landscape
Which to choose in future?
#Ianalumab
#dazodalibep
DIff #MOA
#CD40L
#CD20 deleted+ altered B cell
Signalling
+RCTs of each
Can’t compare between drugs #efficacy
🤷
#ACR2026 @RheumNow @ACRheum
#LB22
#1861 shows #Iana effects https://t.co/73D0ENtcnZ
Janet Pope
Tweet
#FcRn
#efigartigimod
+ #RCT in #IMNM & #DM
#LB24
But
😞 #SjD RCT stopped 🛑 for
#futility
We will have niche Rx for many rare #SARDs I think over next few yrs
#ACR26 @ACRheum @RheumNow
sheila
Tweet
OASIZ-301 Trial- Dazodalibep for SjD
Both DAZ arms (3000mg & 1500mg) demonstrated sign. improvements in ESSDAI at wk 48 vs PBO
DAZ arms also met key sec endpts - including sign. improved ESSPRI/DASPRI dryness domains w/1500mg
Both arms safe & welltolerated
@RheumNow #ACR26 LB22 https://t.co/GjnDCWkMG7
Richard Conway
Tweet
Noaiseh et al. Phase 3 OASIZ-301 RCT. Dazodalibep in Sjogens. Positive study. Effect by week 4. Secondary outcomes on sicca also met. Similar adverse events to placebo. @RheumNow #ACR26 Abstr#LB22 https://t.co/s4E44IMpS8
Janet Pope
Tweet
#Dazodolibep #RCT in #SjD #CD40Li fusion protein no Fc 3 arms - 2 protocols ⬆️signs #ESSDAI>5. Entered >10 Other ⬆️#ESSPRI #Sjogren’s 1 or 2ndary (25%) 93%F -1.8 diff from PBO +results #ACRbest new Rx! #LB22 #ACR26 #ACRbest @RheumNow @ACRheum https://t.co/JJaDp0nCnM
Akhil Sood MD, MS
Tweet
Another potential treatment for treating Sjogren's:
LB22: Ph3b efficacy & safety of Dazodalibep (DZP), CD40/CD40L inhbition
VS PBO:
- Wk 48; both DZP regimens improved ESDAI (diff v PBO -1.8 & -1.4)
- tx effect early as wk 4
- Pt reported dryness also improved
@RheumNow #ACR26 https://t.co/qa4dyr3e40
Adela Castro
Tweet
Lip biopsy for Sjogren's disease diagnosis?
Great debate at #ACR26 @RheumNow
Audrey Gibson
Tweet
Dörner et al: The NEPTUNUS extension examines longer-term ianalumab treatment in Sjögren's disease after positive phase 3 trials. Durability, safety and sustained disease control are the questions to watch. @rheumnow #ACR2026 Abstract#LB14
Audrey Gibson
Tweet
Could familiar DMARDs become a treatment strategy for Sjögren's?
The NECESSITY trial reports efficacy with HCQ + leflunomide and HCQ + MMF combinations.
An intriguing potential option while targeted treatment development continues.
#LB15 @RheumNow #ACR26
Audrey Gibson
Tweet
Sjögren's treatment is entering a new era! Long-term NEPTUNUS extension data examine durability and safety of ianalumab, a BAFF-R–targeting antibody, Phase 3 results. Dörner et al. | #LB14 @RheumNow #ACR26
Richard Conway
Tweet
Mariette et al. NECESSITY trial in primary Sjogren's disease. New response measure (STAR). Responders at W24 was 24.3% with placebo, 54.4% with HCQ + MMF (p< 0.001) and 52.4% with HCQ + LEF (p< 0.001). @RheumNow #ACR26 Abstr#LB15 #ACRbest https://t.co/sIQcC3KKSD
Licia Mota
Tweet
Not all ILD is created equal
#ACR26 Abstract 1375: RA-ILD showed a fibrotic, UIP-predominant phenotype (64% vs 37% in Sjögren), while Sjögren-ILD was more inflammatory.
Different phenotypes, different monitoring strategies, even with similar FVC trajectories.
@RheumNow #ACR26 https://t.co/yWnnX1Y6Wv
#ACR26 – Big Pharma Brings Its Biggest Readouts to Orlando
ACR Convergence 2026 runs November 6–11 in Orlando, and the major companies will be presenting their highlight trials this week. Phase 3 results in Sjögren's and gout headline the late-breaking orals, while plenaries https://t.co/WPYb7AkoI2
CD40 modulation: unfamiliar but promising MOA in rheumatology esp re; SjD
CD40 mediates crosstalk between T + B cells Dazodalibep (DAZ) and Iscalimab currently in development.
DAZ SjD trial dropping as late breaking abstract LB22 on Wed 11/11 #ACR26 @RheumNow https://t.co/hzIedKV3kE
